KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Research & Development (2016 - 2022)

TherapeuticsMD (TXMD) has disclosed Research & Development for 12 consecutive years, with $1.1 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Research & Development fell 30.72% year-over-year to $1.1 million, compared with a TTM value of $5.5 million through Sep 2022, down 31.61%, and an annual FY2021 reading of $7.1 million, down 32.07% over the prior year.
  • Research & Development was $1.1 million for Q3 2022 at TherapeuticsMD, down from $1.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $7.0 million in Q1 2018 and bottomed at $1.1 million in Q3 2022.
  • Average Research & Development over 5 years is $3.6 million, with a median of $2.7 million recorded in 2020.
  • The sharpest move saw Research & Development rose 4.22% in 2018, then tumbled 50.29% in 2020.
  • Year by year, Research & Development stood at $6.8 million in 2018, then tumbled by 34.37% to $4.4 million in 2019, then tumbled by 45.98% to $2.4 million in 2020, then tumbled by 40.69% to $1.4 million in 2021, then fell by 21.69% to $1.1 million in 2022.
  • Business Quant data shows Research & Development for TXMD at $1.1 million in Q3 2022, $1.6 million in Q2 2022, and $1.4 million in Q1 2022.